FI107607B - Förfarande för framställning av terapeutiskt användbart 1,4-piperidinderivat - Google Patents

Förfarande för framställning av terapeutiskt användbart 1,4-piperidinderivat Download PDF

Info

Publication number
FI107607B
FI107607B FI944044A FI944044A FI107607B FI 107607 B FI107607 B FI 107607B FI 944044 A FI944044 A FI 944044A FI 944044 A FI944044 A FI 944044A FI 107607 B FI107607 B FI 107607B
Authority
FI
Finland
Prior art keywords
methyl
phenylmethyl
formula
phenyl
mol
Prior art date
Application number
FI944044A
Other languages
English (en)
Finnish (fi)
Other versions
FI944044A0 (sv
FI944044A (sv
Inventor
Erno Mohacsi
Jay Philip O'brien
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of FI944044A0 publication Critical patent/FI944044A0/sv
Publication of FI944044A publication Critical patent/FI944044A/sv
Application granted granted Critical
Publication of FI107607B publication Critical patent/FI107607B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Table Devices Or Equipment (AREA)
  • Fats And Perfumes (AREA)
  • Organic Insulating Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Solid Fuels And Fuel-Associated Substances (AREA)
  • Indole Compounds (AREA)

Claims (5)

1. Förfarande för framställing av ett terapeutiskt användbart 1,4-piperidinderivat med formeln I »jO^CuD 10 samt enantiomerer, diastereomerer och farmaceutiskt god-tagbara salter därav, kännetecknat därav, att man a) reducerar en förening med formeln IA med hjälp av väte i närvaro av en lämplig katalysator, säsom palladium pä koi eller med hjälp av ett al-kalime-20 tallhydridkomplex, säsom litiumaluminium- eller kalium-borhydrid, eller «·!· b) debensylerar en förening med formeln III ···· • · · I “ c.wJO'WxjO 1,1 • · « • · · eller *:**: c) för att framställa en optiskt ren förening med ·***: 30 formeln I, upplöser ett racemat tili enantiomeriska «· · • *. andelar därav, och • e · • · · i fall önskvärt, omvandlar en förening med formeln • · ’·;·* I tili ett farmaceutiskt godtagbart sait. * :*: 2. Förfarande enligt patentkrav 1, kännetecknat • · · · 35 därav, att man framställer 107607 (R*,S*)-rac-α-(4-hydroxfenyl)-B-metyl-4-(fe-nylmetyl)-1-piperidinpropanol.
3. Förfarande enligt patentkrav 1, kännetecknat därav, att man framställer [R-(R*,S*)]-a-(4-hydroxfenyl)-
5 B-metyl-4-(fenylmetyl)-1-piperidin-propanol.
4. Förfarande enligt patentkrav 1, kännetecknat därav, att man framställer [S-(R*,S*)]-a-(4-hydroxfenyl)-B-metyl-4-(fenylmetyl)-1-piperidinpro-panol.
5. Förfarande enligt patentkrav 1, kännetecknat ίο därav, att man framställer (R*,R*)-rac-α—(4-hydroxfenyl)- B-metyl-4-(fenylmetyl)-1-piperidinpro-panol. • Ml Φ • · · · Ml MM «·« • · * · • · · Φ « · • ·· · Ml • Ml ··· I I « • · · • · ··« t t ··· • · · I I I IM • · · $ 9 • · • · · • · III ( I I IM · 1 $ 9
FI944044A 1993-09-02 1994-09-02 Förfarande för framställning av terapeutiskt användbart 1,4-piperidinderivat FI107607B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11638593A 1993-09-02 1993-09-02
US11638593 1993-09-02

Publications (3)

Publication Number Publication Date
FI944044A0 FI944044A0 (sv) 1994-09-02
FI944044A FI944044A (sv) 1995-03-03
FI107607B true FI107607B (sv) 2001-09-14

Family

ID=22366865

Family Applications (1)

Application Number Title Priority Date Filing Date
FI944044A FI107607B (sv) 1993-09-02 1994-09-02 Förfarande för framställning av terapeutiskt användbart 1,4-piperidinderivat

Country Status (22)

Country Link
EP (1) EP0648744B1 (sv)
JP (1) JP2610784B2 (sv)
KR (1) KR100360954B1 (sv)
CN (1) CN1061035C (sv)
AT (1) ATE162520T1 (sv)
AU (1) AU7149794A (sv)
BR (1) BR9403418A (sv)
CA (1) CA2129771C (sv)
CZ (1) CZ210694A3 (sv)
DE (1) DE69408078T2 (sv)
DK (1) DK0648744T3 (sv)
ES (1) ES2113585T3 (sv)
FI (1) FI107607B (sv)
GR (1) GR3026622T3 (sv)
HU (1) HUT70558A (sv)
IL (1) IL110812A0 (sv)
NO (1) NO943231L (sv)
NZ (1) NZ264320A (sv)
PL (1) PL304863A1 (sv)
RU (1) RU94031753A (sv)
TW (1) TW281670B (sv)
ZA (1) ZA946529B (sv)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658909A (en) 1994-11-17 1997-08-19 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1'-yl propanones to treat Alzheimer's Disease
US6214994B1 (en) 1997-04-21 2001-04-10 Molecular Geriatrics Corporation Certain substituted 1-aryl-3-piperazin-1′-yl propanones
US5693804A (en) * 1994-11-17 1997-12-02 Molecular Geriatrics Corporation Substituted 1-aryl-3-piperazin-1'-yl propanones
FR2742051B1 (fr) * 1995-12-06 1998-02-06 Synthelabo Utilisation de composes ayant une affinite pour le site de liaison du (3h)ifenprodil pour la fabrication de medicaments utiles dans la prevention et le traitement des neuropathies
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
PL340080A1 (en) 1997-10-24 2001-01-15 Warner Lambert Co Method of treating disease-related or post-drug dyskinesias
GB9804885D0 (en) 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
SI1409477T1 (sl) * 2001-07-24 2009-02-28 Richter Gedeon Nyrt Derivati piperidina kot antagonisti nmda-receptorjev
JP4737418B2 (ja) 2003-09-25 2011-08-03 塩野義製薬株式会社 Ｎｍｄａ受容体拮抗作用を有するピペリジン誘導体
MX2014004469A (es) 2011-11-22 2014-08-01 Univ California Metodos y composiciones para tratar inflamacion y lesion isquemica.
RU2649406C1 (ru) * 2017-09-21 2018-04-03 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) 3-n-замещенные борнилпропионаты, используемые в качестве ингибиторов вируса марбург

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4261285A (en) * 1984-06-01 1985-12-05 Tokyo Tanabe Company Limited 1-propanone derivatives
DE3433036A1 (de) * 1984-09-08 1986-03-20 Basf Ag, 6700 Ludwigshafen Piperidinderivate und diese enthaltende fungizide sowie verfahren zur bekaempfung von pilzen
EP0398578B1 (en) * 1989-05-17 1997-03-12 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
US4940789A (en) * 1989-10-10 1990-07-10 American Home Products Corporation 10,11-dihydro-5-alkyl-12-substituted-10,5-(iminomethano)-5H-dibenzo[a,d]cycloheptenes as neuroprotectant agents
JP3094450B2 (ja) * 1990-10-15 2000-10-03 アストラゼネカ・アクチエボラーグ 神経保護特性を有するピペリジン誘導体
SE9003652D0 (sv) * 1990-11-15 1990-11-15 Astra Ab New heterocyclic compounds

Also Published As

Publication number Publication date
FI944044A0 (sv) 1994-09-02
EP0648744B1 (en) 1998-01-21
NO943231L (no) 1995-03-03
FI944044A (sv) 1995-03-03
ATE162520T1 (de) 1998-02-15
RU94031753A (ru) 1996-07-20
TW281670B (sv) 1996-07-21
NO943231D0 (no) 1994-09-01
CN1105990A (zh) 1995-08-02
BR9403418A (pt) 1996-09-03
CA2129771A1 (en) 1995-03-03
CA2129771C (en) 2006-03-21
AU7149794A (en) 1995-03-16
IL110812A0 (en) 1994-11-11
DK0648744T3 (da) 1998-09-21
HUT70558A (en) 1995-10-30
EP0648744A1 (en) 1995-04-19
CZ210694A3 (en) 1995-08-16
ZA946529B (en) 1995-03-02
PL304863A1 (en) 1995-03-06
JP2610784B2 (ja) 1997-05-14
HU9402479D0 (en) 1994-10-28
NZ264320A (en) 1996-02-27
CN1061035C (zh) 2001-01-24
KR950008481A (ko) 1995-04-17
DE69408078D1 (de) 1998-02-26
GR3026622T3 (en) 1998-07-31
DE69408078T2 (de) 1998-07-09
JPH0782250A (ja) 1995-03-28
KR100360954B1 (ko) 2003-04-16
ES2113585T3 (es) 1998-05-01

Similar Documents

Publication Publication Date Title
FI107607B (sv) Förfarande för framställning av terapeutiskt användbart 1,4-piperidinderivat
US7951821B2 (en) N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy
US5981520A (en) Piperazino derivatives as neurokinin antagonists
US5340822A (en) Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions in which they are present
DE60225162T3 (de) Phenylpiperazinderivate als serotonin wiederaufnahmehemmer
EP1499589B1 (fr) Derives de n-¬phenyl(piperidin-2-yl)methyl|benzamide, leur preparation et leur application en therapeutique
RU2351588C2 (ru) Производные n-фенил(пиперидин-2-ил)метил-бензамида и их применение в терапии
KR100523366B1 (ko) 티에닐아졸일알콕시에탄아민, 이의 제조방법 및 이의 용도
US6071932A (en) Carbazolypiperines as GABA uptake inhibitors
US6642257B2 (en) Agents for treating neuropathic pain
AU603004B2 (en) 1-((2-pyrimidinyl)aminoalkyl)piperidines, their preparation and their application in therapy
EA011635B1 (ru) Новые производные амида гетероциклической карбоновой кислоты
EA011241B1 (ru) Новые производные 4-бензилиденпиперидина
JPS6135175B2 (sv)
RU2418794C2 (ru) ПРОИЗВОДНЫЕ ИЗОХИНОЛИНА И БЕНЗО[h]ИЗОХИНОЛИНА, ИХ ПОЛУЧЕНИЕ И ИХ ПРИМЕНЕНИЕ В ТЕРАПИИ В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРА ГИСТАМИНА H3
WO2006010966A1 (en) New benzoyl urea derivatives
DE60130691T2 (de) Indolderivate zur Behandlung von Erkrankungen des Zentralnervensystems
HU221633B1 (hu) Neuroprotektív krománvegyületek és az ezeket tartalmazó gyógyszerkészítmények
SK286401B6 (sk) Deriváty (1-fenacyl-3-fenyl-3-piperidyletyl)piperidínu, spôsob ich prípravy a farmaceutická kompozícia, ktorá ich obsahuje
EP1785415B1 (en) Piperidine derivative or pharmaceutically acceptable salt thereof
AU619049B2 (en) New 1,4-dihydropyridinederivative, namely (-)-2-{(2- aminoethoxy) ethoxy)-4-(2,3-dichlorophenyl)-3- ethoxycarbonyl-50methoxycarbonyl-6-methyl}-1,4- dihydropyridine, process for preparing it and pharmaceutical compositions containing it
KR20130082453A (ko) 아밀로이드 병리의 치료 및 예방을 위한 플루페녹신 유도체